imatinib

From these, imatinib was found to have the most promise in laboratory experiments.

This new indication has been added to the limited use criteria for Imatinib.

The two year survival of patients with advanced disease has risen to 75-80% following imatinib treatment.

The generic version of the drug is called imatinib.

Physicians have commented that the cost of imatinib is excessive.

'Imatinib' is a medication used to treat certain types of cancer.

In selected higher risk adjuvant situations, imatinib is recommended for 3 years.

Finally a trifluoromethyl group at position 3 was found to give the best results, with approximately 36-fold improvement over imatinib.

Second generation drugs are intended to have decreased resistance and intolerance than imatinib.

These groups also make the shape of nilotinib very different from that of imatinib.

"Using imatinib plus chemotherapy had a synergistic type of interaction.

The anti-cancer drug imatinib has recently been shown to reverse the graying process.

The effectiveness of imatinib and sunitinib depend on the genotype.

Compared to older drugs imatinib has a relatively benign side effect profile, allowing many patients to live a normal lifestyle.

Therefore, kinase inhibitors, such as imatinib, are often effective cancer treatments.

However Imatinib, as an inhibitor to the malfunctioning enzyme, can be effective.

It may also interact with the anti-cancer drugs irinotecan and imatinib.

His main scientific contribution relates to the preclinical and clinical development of imatinib.

They tested five common chemotherapy drugs including Gleevec, also known as imatinib. '

The researchers have shown that the binding of imatinib unexpectedly shifts this equilibrium to the open state.

Tests on mice indicate that imatinib is effective at reducing beta-amyloid in the brain.

Synergistic activity of imatinib and nilotinib has been reported following coadministration.

They gave imatinib to rats that were suffering symptoms similar to humans with MS.

Inhibitor drugs including 'Imatinib' can block key signals and cause the death of the diseased cells.

It was developed based on the structure of the Abl-imatinib complex to address the need associated with imatinib intolerance and resistance.